<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020747</url>
  </required_header>
  <id_info>
    <org_study_id>VC-P001</org_study_id>
    <nct_id>NCT01020747</nct_id>
  </id_info>
  <brief_title>Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)</brief_title>
  <official_title>A Pilot Study to Evaluate the Effects of Antiangiogenic Factor as an Adjunct Treatment After Photoangiolysis in Patients With Bilateral Recurrent Respiratory Papillomatosis of the Vocal Fold</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I single center open labeled study is planned to assess the safety and
      tolerability of bevacizumab for treating patients with bilateral Recurrent Respiratory
      Papillomatosis (RRP). Approximately 20 patients will receive bevacizumab directly injected
      into the vocal folds. Patients who enroll in the protocol will be injected with bevacizumab
      in one vocal fold that represents the more diseased of the two folds. A sham injection with
      saline will be administered to the other vocal fold as the control. This therapy will be
      administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the
      initial treatment always getting the drug injection. The investigator will also treat lesions
      by laser photoangiolysis of both vocal folds using the 532 nm potassium-titanyl-phosphate
      (KTP) laser.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient During and at the End of the 6-month Treatment Period.</measure>
    <time_frame>6 months</time_frame>
    <description>Prior to each treatment,the area of reappearance of disease was measured and the % change from baseline was calculated. The change was then added to the % change from the previous treatment to generate a cumulative total % change of reappearance of RRP from baseline. The additive nature of this parameter resulted in % greater than 100% if the area of vocal fold affected by the RRP increased over the baseline measurement.</description>
  </primary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Recurrent Respiratory Papillomatosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin® (bevacizumab)</intervention_name>
    <description>Bevacizumab injections (~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.</description>
    <other_name>Avastin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with dysphonia that have been diagnosed with Recurrent
             Respiratory Papillomatosis (RRP) of the vocal folds

          -  Age between 18 and 60 years old

          -  Female patients must be surgically sterilized, postmenopausal, or employ adequate
             contraception. Criteria for menopause are surgical menopause (hysterectomy,
             oophorectomy) or age &gt; 45 years with absence of menses for greater than 12 months and
             an elevated serum Hormone, follicle-stimulating (FSH) (&gt; 25 mIU/mL). Tubal ligation
             with menses within the past 12 months is not considered to be surgical sterilization.

          -  Have bilateral glottal papillomatosis (i.e., involving both the right and left vocal
             folds)

          -  Willing and able to comply with the investigational nature of the study and able to
             communicate well with investigators.

          -  Ability to comprehend and willingness to provide written informed consent in
             accordance with institutional and regulatory guidelines.

        Exclusion Criteria:

          -  Have known sensitivity to bevacizumab

          -  Have been treated systemically with bevacizumab within 4 months (approximately 6
             half-lives).

          -  Have hematocrits &lt; 30, elevated PT or PTT levels more than 1.2 X the upper limit of
             normal (ULN) or absolute platelet counts below the lower limit of normal (LLN).

          -  Have absolute neutrophil counts below 1500

          -  Have urine dipsticks positive for ≥3+ proteinuria will have spot urine collections and
             those patients with urine protein to urine creatinine ratios greater than 1.5.

          -  Have a history of congestive heart failure, angina that remains symptomatic despite
             medications, myocardial infarction or coronary artery disease-related procedure within
             the past 6 months (including angioplasty, stent placement, bypass graft surgery) or
             who have prosthetic heart valves.

          -  Have significant uncontrolled hypertension (systolic blood pressure above 160 and/or
             diastolic blood pressure above 100).

          -  Have had surgeries within 1 month of enrollment or who have un-healed surgical
             incisions at screening.

          -  Have a history of thromboembolic events, gastro-intestinal (GI) ulcer or bleeding, or
             with a history of wound dehiscence.

          -  Female patients that are pregnant, nursing or plan to nurse during the up to 18 months
             of treatment period.

          -  Patients with a history of bleeding disorders, documented platelet dysfunction,
             current use of anti-platelet drugs, or abnormal prothrombin time (PT) or activated
             partial thromboplastin timea (PTT) laboratory values as defined in number 3 above.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Zeitels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.gene.com/gene/products/information/oncology/avastin</url>
    <description>Avastin package insert and information from the Genentech website.</description>
  </link>
  <link>
    <url>http://www.rrpwebsite.org/</url>
    <description>International RRP ISA site</description>
  </link>
  <link>
    <url>http://www.rrpf.org/</url>
    <description>RRP Foundation website</description>
  </link>
  <reference>
    <citation>Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science. 1983 Apr 29;220(4596):524-7.</citation>
    <PMID>6836297</PMID>
  </reference>
  <reference>
    <citation>Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg. 1999 Jul;125(7):743-8.</citation>
    <PMID>10406310</PMID>
  </reference>
  <reference>
    <citation>Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006 Mar;113(3):363-372.e5. Epub 2006 Feb 3.</citation>
    <PMID>16458968</PMID>
  </reference>
  <reference>
    <citation>Burns JA, Zeitels SM, Akst LM, Broadhurst MS, Hillman RE, Anderson R. 532 nm pulsed potassium-titanyl-phosphate laser treatment of laryngeal papillomatosis under general anesthesia. Laryngoscope. 2007 Aug;117(8):1500-4.</citation>
    <PMID>17585283</PMID>
  </reference>
  <reference>
    <citation>Dedo HH, Yu KC. CO(2) laser treatment in 244 patients with respiratory papillomas. Laryngoscope. 2001 Sep;111(9):1639-44.</citation>
    <PMID>11568620</PMID>
  </reference>
  <reference>
    <citation>Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91.</citation>
    <PMID>7488368</PMID>
  </reference>
  <reference>
    <citation>Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18. Review.</citation>
    <PMID>16409133</PMID>
  </reference>
  <reference>
    <citation>Franco RA Jr, Zeitels SM, Farinelli WA, Anderson RR. 585-nm pulsed dye laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol. 2002 Jun;111(6):486-92.</citation>
    <PMID>12090703</PMID>
  </reference>
  <reference>
    <citation>Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006 Nov;90(11):1344-9. Epub 2006 Jul 19.</citation>
    <PMID>16854824</PMID>
  </reference>
  <reference>
    <citation>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.</citation>
    <PMID>15175435</PMID>
  </reference>
  <reference>
    <citation>Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand. 2007 Feb;85(1):119-20.</citation>
    <PMID>17244226</PMID>
  </reference>
  <reference>
    <citation>Meert AP, Feoli F, Martin B, Ninane V, Sculier JP. Angiogenesis in preinvasive, early invasive bronchial lesions and micropapillomatosis and correlation with EGFR expression. Histopathology. 2007 Feb;50(3):311-7.</citation>
    <PMID>17257126</PMID>
  </reference>
  <reference>
    <citation>Mounts P, Shah KV, Kashima H. Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5425-9.</citation>
    <PMID>6291043</PMID>
  </reference>
  <reference>
    <citation>Parsons DS, Bothwell MR. Powered instrument papilloma excision: an alternative to laser therapy for recurrent respiratory papilloma. Laryngoscope. 2001 Aug;111(8):1494-6.</citation>
    <PMID>11568590</PMID>
  </reference>
  <reference>
    <citation>Rahbar R, Vargas SO, Folkman J, McGill TJ, Healy GB, Tan X, Brown LF. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2005 Apr;114(4):289-95.</citation>
    <PMID>15895784</PMID>
  </reference>
  <reference>
    <citation>Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol. 2004 Oct;22(10):1198.</citation>
    <PMID>15470443</PMID>
  </reference>
  <reference>
    <citation>Sachdev JC, Jahanzeb M. Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer. 2008 Oct;8(5):402-10. doi: 10.3816/CBC.2008.n.048. Review.</citation>
    <PMID>18952553</PMID>
  </reference>
  <reference>
    <citation>Shehab N, Sweet BV, Hogikyan ND. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy. 2005 Jul;25(7):977-89. Review.</citation>
    <PMID>16006276</PMID>
  </reference>
  <reference>
    <citation>Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006 Apr;26(4):383-90.</citation>
    <PMID>16603955</PMID>
  </reference>
  <reference>
    <citation>Steinberg BM, DiLorenzo TP. A possible role for human papillomaviruses in head and neck cancer. Cancer Metastasis Rev. 1996 Mar;15(1):91-112. Review.</citation>
    <PMID>8842481</PMID>
  </reference>
  <reference>
    <citation>Strong MS, Vaughan CW, Cooperband SR, Healy GB, Clemente MA. Recurrent respiratory papillomatosis: management with the CO2 laser. Ann Otol Rhinol Laryngol. 1976 Jul-Aug;85(4 Pt 1):508-16.</citation>
    <PMID>949157</PMID>
  </reference>
  <reference>
    <citation>Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):81-7. Epub 2007 Aug 3.</citation>
    <PMID>17674014</PMID>
  </reference>
  <reference>
    <citation>Zeitels, S.M. (2001). In Atlas of Phonomicrosurgery and Other Endolaryngeal Procedures for Benign and Malignant Disease (San Diego).</citation>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <results_first_submitted>April 23, 2012</results_first_submitted>
  <results_first_submitted_qc>November 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2012</results_first_posted>
  <last_update_submitted>December 18, 2012</last_update_submitted>
  <last_update_submitted_qc>December 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven M. Zeitels, MD, FACS</investigator_full_name>
    <investigator_title>Director: Center for Laryngeal Surgery and Voice Rehabilitation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group Avastin</title>
          <description>Subjects received Avastin in the more diseased vocal fold and saline in the other.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group Avastin</title>
          <description>Subjects received Avastin in the more diseased vocal fold and saline in the other.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.5" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient During and at the End of the 6-month Treatment Period.</title>
        <description>Prior to each treatment,the area of reappearance of disease was measured and the % change from baseline was calculated. The change was then added to the % change from the previous treatment to generate a cumulative total % change of reappearance of RRP from baseline. The additive nature of this parameter resulted in % greater than 100% if the area of vocal fold affected by the RRP increased over the baseline measurement.</description>
        <time_frame>6 months</time_frame>
        <population>All subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab Treated Vocal Fold</title>
            <description>Subjects received injections of bevacizumab in conjunction with Potassium-Titanyl-Phosphate (KTP)laser photoangiolysis in the more diseased vocal fold.</description>
          </group>
          <group group_id="O2">
            <title>Untreated Vocal Fold</title>
            <description>Subjects received saline injections in combination with Potassium-Titanyl-Phosphate (KTP)laser photoangiolysis in the less diseased vocal fold.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient During and at the End of the 6-month Treatment Period.</title>
          <description>Prior to each treatment,the area of reappearance of disease was measured and the % change from baseline was calculated. The change was then added to the % change from the previous treatment to generate a cumulative total % change of reappearance of RRP from baseline. The additive nature of this parameter resulted in % greater than 100% if the area of vocal fold affected by the RRP increased over the baseline measurement.</description>
          <population>All subjects were analyzed.</population>
          <units>total percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" spread="68.6"/>
                    <measurement group_id="O2" value="225.3" spread="191.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The main treatment period lasted 6 months for each subject. Adverse events were captured for all subjects for a period of 26 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group Avastin</title>
          <description>Subjects received Avastin in the more diseased vocal fold and saline in the other.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>no coding</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye twitching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>tooth ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>flu-like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>oversedation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>tongue numbness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>disk herniation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aguesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>cough/URI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diminished voice volume</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>drainage and congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>higher pitch</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hoarseness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>poison ivy rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>toe (right) cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Monica Tettamanti</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-643-5696</phone>
      <email>mtettamanti@ccib.mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

